CellWell record HH-1117
Screening for Ovarian Cancer: Recommendation Statement
Prostate, Lung, Colorectal
and Ovarian (PLCO) Cancer Screening Trial
In plain language
CA-125 + transvaginal ultrasound screening (78,216 women, median 12.4-year follow-up) did not reduce ovarian-cancer-specific or overall mortality; false-positive rate 9.6%, surgery in 3.17% of false-positive women.
- Design
- Clinical trial
Cite this record: https://thecellwell.org/studies/HH-1117
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.